BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND TET1, KIAA1676, 80312, ENSG00000138336, CXXC6, bA119F7_1, Q8NFU7, LCX AND Clinical Outcome
753 results:

  • 1. m
    Wu Y; Li L; Wang L; Zhang S; Zeng Z; Lu J; Wang Z; Zhang Y; Zhang S; Li H; Chen T
    BMC Cancer; 2024 Apr; 24(1):506. PubMed ID: 38649860
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
    Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
    Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tumor cell-derived LC3B
    Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
    Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma.
    Demir S; Razizadeh N; Indersie E; Branchereau S; Cairo S; Kappler R
    Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285887
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
    Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
    Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.
    Xie LL; Huang YB; Dong KR; Yang SB; Shen C; Ma YY
    BMC Pediatr; 2024 Jan; 24(1):8. PubMed ID: 38172842
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
    Sacco M; Ribaldone DG; Saracco GM
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
    Yin L; Yin AH; Pu CC
    BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comparison of clinical outcome between laparoscopic and open hepatectomy of high difficulty score for hepatocellular carcinoma: a propensity score analysis.
    Ng KKC; Cheng KC; Kung JWC; Ho KM; Lok HT; Fung AKY; Chong CCN; Cheung SYS; Lee KF; Wong J; Lai PBS
    Surg Endosc; 2024 Feb; 38(2):857-871. PubMed ID: 38082015
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial.
    Vogl TJ; Martin SS; Gruber-Rouh T; Booz C; Koch V; Nour-Eldin NA; Hussainy Said MN
    Rofo; 2024 May; 196(5):482-490. PubMed ID: 38065541
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Development and evaluation of a risk score model based on a WNT score gene-associated signature for predicting the clinical outcome and the tumour microenvironment of hepatocellular carcinoma.
    Li P; Ma X; Huang D; Gu X
    Int J Immunopathol Pharmacol; 2023; 37():3946320231218179. PubMed ID: 38054921
    [No Abstract]    [Full Text] [Related]  

  • 12. Intelectin-1 is a novel prognostic biomarker for hepatocellular carcinoma.
    Li J; Tao HS; Yuan T; Huang ZY; Zhang EL
    Medicine (Baltimore); 2023 Dec; 102(48):e36474. PubMed ID: 38050235
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
    Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
    Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.
    Amin MN; El-Far YM; El-Mowafy M; Elgaml A
    Clin Epigenetics; 2023 Nov; 15(1):180. PubMed ID: 37941056
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation.
    Xu LB; Qin YF; Su L; Huang C; Xu Q; Zhang R; Shi XD; Sun R; Chen J; Song Z; Jiang X; Shang L; Xiao G; Kong X; Liu C; Wong PP
    Nat Commun; 2023 Nov; 14(1):7033. PubMed ID: 37923799
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Case Report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor.
    Wang Q; Mu Y; Ji S; Liu Y; Lou Y; Wei S; Dong X; Zhang B
    Front Immunol; 2023; 14():1173520. PubMed ID: 37841278
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Optimal Follow-up of Incidental Pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
    Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
    Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. SETD1A drives stemness by reprogramming the epigenetic landscape in hepatocellular carcinoma stem cells.
    Chen J; Xu Z; Huang H; Tang Y; Shan H; Xiao F
    JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37581938
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
    Huang H; Tsui YM; Ho DW; Chung CY; Sze KM; Lee E; Cheung GC; Zhang VX; Wang X; Lyu X; Ng IO
    Hepatology; 2024 Feb; 79(2):323-340. PubMed ID: 37540188
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 38.